dpp-4_inhibitors [TUSOM
US$ 29.57
glp-1 covered by cigna Health insurer will stop covering weight loss drugs in its employee health plan US is only country debating
Description
By product type, the GLP-1 receptor agonists segment held the largest market share in 2025 and is expected to grow at the fastest CAGR during the projection period
Furthermore, veterinary use mandates additional safety assessments to detect unforeseeable side effects in animals, ensuring a holistic approach to pet healthcare
Despite this scale, no drug therapies have been approved to treat the condition
As of July 1, there were 3,848 pending actions in the MDL
10.1016/S0140-6736(18)32261-X
